Review Article

Recent Advance in Source, Property, Differentiation, and Applications of Infrapatellar Fat Pad Adipose-Derived Stem Cells

Yu-chen Zhong,1,2 Shi-chun Wang,1,2 Yin-he Han,1 and Yu Wen1

1Department of Histology and Embryology, College of Basic Medical Sciences, China Medical University, Shenyang 110122, China
2Class 4, Phase 102, China Medical University, Shenyang 110122, China

Correspondence should be addressed to Yu Wen; ywen@cmu.edu.cn

Received 13 December 2019; Revised 12 February 2020; Accepted 20 February 2020; Published 7 March 2020

Academic Editor: Leonard M. Eisenberg

Copyright © 2020 Yu-chen Zhong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infrapatellar fat pad (IPFP) can be easily obtained during knee surgery, which avoids the damage to patients for obtaining IPFP. Infrapatellar fat pad adipose-derived stem cells (IPFP-ASCs) are also called infrapatellar fat pad mesenchymal stem cells (IPFP-MSCs) because the morphology of IPFP-ASCs is similar to that of bone marrow mesenchymal stem cells (BM-MSCs). IPFP-ASCs are attracting more and more attention due to their characteristics suitable to regenerative medicine such as strong proliferation and differentiation, anti-inflammation, antiaging, secreting cytokines, multipotential capacity, and 3D culture. IPFP-ASCs can repair articular cartilage and relieve the pain caused by osteoarthritis, so most of IPFP-related review articles focus on osteoarthritis. This article reviews the anatomy and function of IPFP, as well as the discovery, amplification, multipotential capacity, and application of IPFP-ASCs in order to explain why IPFP-ASC is a superior stem cell source in regenerative medicine.

1. Introduction

In knee arthroplasty, infrapatellar fat pad (IPFP) as an inflamed tissue must be resected to relieve pain, so obtaining infrapatellar fat pad adipose-derived stem cells (IPFP-ASCs) avoids the secondary damage to patients as compared with obtaining mesenchymal stem cells (MSCs) derived from bone marrow, synovium, and subcutaneous fat. IPFP contains a large number of stem cells (5.5 × 10⁶ stem cells in 21 ml of IPFP), so more stem cells may be obtained from IPFP than from bone marrow [1].

Due to the presence of telomerase activity which can delay the aging process, IPFP-ASCs have strong proliferation capability and differentiation potential, namely, that IPFP-ASCs can be purified by multiple passages and then show stable differentiation potential [2]. Moreover, IPFP-ASCs are more superior in chondrogenic differentiation and osteogenic differentiation than bone marrow mesenchymal stem cells (BM-MSCs) [3] and synovial fluid mesenchymal stem cells (SF-MSCs) [4]. Due to IPFP anatomical position, the surface markers of IPFP-ASCs are similar to those of other cells around the knee joint, so IPFP-ASCs can be implanted in the knee joint with other synthetic grafts to reduce immunologic rejection [5]. IPFP-ASC is a good seed cell for autologous or allogenic stem cell transplantation because of its strong proliferation capability and weak immunologic rejection [6, 7].

IPFP, a subsidiary tissue to protect and support the knee joint, may have repair effects on the knee joint by secreting cytokines [8]. Currently, it is difficult for osteoarthritis to repair knee joint tissue and control disease progression due to weak regeneration capability and reduced blood supply [5], so the treatment for osteoarthritis focuses on relieving pain and protecting remaining joint function. In recent years, it is reported that autologous stem cell transplantation has a certain therapeutic effect on osteoarthritis [9]; SF-MSCs can repair cartilage, mesenchymal stem cells (MSCs) can relieve inflammatory pain by secreting prostaglandin E2 (PGE2) regulating the expression of inflammatory factors in surrounding cells, and the injection of supernatant fluid after
IPFP-ASC culture into the knee joint can relieve inflammatory pain and restore partial joint function [10]. Therefore, IPFP has both physical protection effect and repair effect provided by paracrine secretion on the knee joint.

Scaffolds are usually used to improve stem cell molding growth. Compared with BM-MSCs and subcutaneous adipose-derived stem cells (Sc-ASCs), IPFP-ASCs grow better in the environment with scaffolds [11]. It is reported that IPFP-ASCs have a good application future in 3D bioprinting [12]. Therefore, IPFP-ASCs are more suitable to molding culture.

IPFP-ASC has become a focus in regenerative medicine and tissue engineering because IPFP-ASCs can be differentiated into bone, cartilage, and fat. Therefore, we reviewed the anatomy and function of IPFP, as well as the discovery, amplification, multipotential capacity, and application of IPFP-ASCs in order to explain why the IPFP-ASC is a high-quality source of stem cells for regenerative medicine. The review article provides a reference for clinical surgical treatment and regenerative medicine.

2. Anatomical Structure and Physiological Function of IPFP

IPFP, yellowish adipose tissue, is located among the patellar tendon, femoral condyle, and tibial plateau with a triangular shape. The tip of the IPFP is attached to the front of the intercondylar fossa, the bottom of the IPFP is below the basis patellae and on both sides of the patellar tendon, and the partial bottom is between the two-layer synovium. IPFP is an inverted triangle in shape, and the two angles of IPFP are located on both sides of the patellar tendon; the inner side of IPFP exceeds the medial margin of the patellar ligament about 2.5 cm, and the outer side of IPFP exceeds the lateral margin of the patellar ligament about 2.4 cm; IPFP stretches about 2 cm upward and about 1 cm outward, and IPFP finally is closely attached to the patellar medial inferior and lateral inferior sides, respectively [13]. In knee bend, IPFP enters the joint cavity to fill the empty space; while in strong contraction of the quadriceps femoris, the IPFP plays a role in preventing knee joint hypermobility. However, once IPFP hardens, IPFP may grow into the joint cavity and cause the limitation of joint motion. The blood supply of IPFP is mainly from the artery genu inferior medialis and artery genu inferior lateralis.

The main physiological function of IPFP is to reduce friction and protect knee joint during joint motion. IPFP can prevent patellar injury by stabilizing patella and reducing friction [14]. Takatoku et al. [15] have found that IPFP is very important for patellar formation and development in immature rabbits. Besides cushioning shock and reducing friction, IPFP has a fixed effect on joint movement. IPFP also has repair effects on the injured knee joint because IPFP-ASCs in IPFP can differentiate into cartilage and can secrete cytokines such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF), which play antiapoptotic roles along with transforming growth factor-β (TGF-β).

3. Comparison of IPFP-ASCs with Other MSCs

Since Zuk et al. [16] discovered and cultured processed lipoaspirate (PLA) cells in 2001, a great deal of attention has been paid to adipose-derived stem cells (ASCs). In 2003, Wickham et al. [17] isolated stromal cells which can be differentiated into bone, cartilage, and fat from IPFP for the first time, providing a basis for investigating MSCs. The application of MSCs in tissue repair has become a hot issue in regenerative medicine and has attracted a great deal of attention from many research studies. Therefore, it is very important to choose a superior stem cell source. MSCs are mainly derived from bone marrow, synovium, subcutaneous adipose tissue, and IPFP. The MSCs derived from various sources are different in differentiation potential, proliferation rate, and surface markers. The surface markers are similar between IPFP-ASCs and BM-MSCs, but different surface markers between IPFP-ASCs and BM-MSCs are also present in some samples, which may be related to the different physiological status of samples and different culture conditions of stem cells.

Garcia et al. [4] have reported that the proliferation capability of SF-MSCs is weaker than that of IPFP-ASCs. Compared with Sc-ASCs, the differentiation capability is stronger and the cell volume is smaller in IPFP-ASCs [12, 18]. CD34 and CD45 expression levels are higher in IPFP-ASCs than in BM-MSCs; and cartilage gene expression levels, especially SOX9 and COL2A1, are more active in IPFP-ASCs than in Sc-ASCs and Wharton’s jelly stem cells (WJSCs) [5]. The above studies suggest that IPFP-ASC has marked advantages in proliferation and differentiation, especially in chondrogenic differentiation, and its strong proliferation capability provides a basis for subsequent large-scale studies. Culture efficiency and surface markers of MSCs from different sources are shown in Table 1.

3.1. Differentiation Potential of MSCs from Different Sources Associated with the Growth Microenvironment and the Paracrine of Surrounding Cells. There is a lot of dense connective tissue around IPFP; but around Sc-ASCs, there is a great deal of subcutaneous tissue. The different growth microenvironments and paracrine of surrounding cells influence their proliferation capability and differentiation potential [26]. IPFP-ASCs can maintain stable chondrogenic differentiation potential during proliferation [3]. In addition, different cytokines, culture methods, and growth microenvironments are associated with IPFP-ASC differentiation potential, which will be introduced in detail in Section 4.3 of this article.

3.2. Proliferative Stability of MSCs from Different Sources Probably Determined by the Integrity of Telomere. Telomere is a nucleoprotein located in the terminal end of the eukaryotic chromosome, and its length is regarded as a biomarker of aging. The maintenance of telomerase activity suggests that the cells have antiaging ability [27]. Until the 18th passage, IPFP-ASCs still have a growth rate and adipogenic differentiation potential which is confirmed by peroxisome proliferator-activated receptor γ2 and lipoprotein
lipase [28]. This may be that IPFP-ASCs possess telomerase activity and telomere integrity, which allow IPFP-ASCs to have mitotic potential after multiple passages [2]. These findings prove IPFP-ASC proliferation capability and also provide an idea for future studies.

3.3. Effects of Different Physiological Conditions on Proliferation Capability and Differentiation Potential of MSCs. In different physiological conditions, IPFP-ASCs have different proliferation capability and differentiation potential. In some knee joint diseases such as localized nodular synovitis, Hoffa’s disease, or arthrofibrosis, the physiological function of MSCs from IPFP with different involvement levels is various. Local anesthetics can weaken the adipogenic differentiation potential of IPFP-ASCs [29]. The chondrogenic differentiation potential of IPFP-ASCs is stronger in obese donors than in thin donors [30]. The osteogenic differentiation potential of IPFP-ASCs is stronger in rheumatoid arthritis than in osteoarthritis, which may be related to tissue necrosis factor-α (TNF-α) [31]. Osteoarthritis can affect the chondrogenic differentiation potential of IPFP-ASCs [32]. The decreased chondrogenic differentiation potential of IPFP-ASCs may be associated with the downregulation of TGF-β gene expression in osteoarthritis [33]. It remains to be further investigated whether the IPFP-ASCs with stronger chondrogenic differentiation potential can be obtained by gene knockout.

3.4. Various Differentiation Potential and Proliferation Capability of MSCs from Bodily Different Parts. Oxygen tension can promote the proliferation of BM-MSCs and IPFP-MSCs [34]. Suprapatellar fat pad adipose-derived stem cells (SPFP-ASCs) can specifically express CD105; SPFP-ASCs have stronger chondrogenic differentiation potential and better effects on relieving the symptoms of osteoarthritis in rat models than IPFP-ASCs [35]. Adipose-derived stem cells isolated from liposuspirates have stronger chondrogenic differentiation potential as compared with IPFP-ASCs [36]. Amaral et al. [37] have reported that cartilage cells differentiated by SF-MSCs are more stable and functional than those differentiated by IPFP-ASCs in vitro; but after subcutaneous injection of the two kinds of stem cells, there is no significant difference in differentiation potential between SF-MSCs and IPFP-ASCs in vivo. Above studies suggest that besides growth microenvironment, stem cell differentiation potential and proliferation capability are also related to stem cell sources and culture methods. In order to understand their interactions, it is necessary to further study the physiological process of stem cell proliferation.

### 4. Isolation, Culture, Identification, and Differentiation Potential of IPFP-ASCs

4.1. Isolation and Culture of IPFP-ASCs. Obtaining IPFP-ASCs requires a series of steps, including separation, mechanical digestion, chemical digestion, purification, and plastic attachment. The process includes shearing, collagenase digestion, impurity removal, filtration, centrifugation, supernatant removal, and transfer culture. The usage of collagenase is not uniform. It has been reported that usage of 0.075% collagenase I requires 2 h for digestion [38] and 0.1% collagenase I combined with one percentage of bovine serum containing CaCl2 requires one hour for digestion [9], while there also is the usage of 0.25% trypsin which requires 20 min for digestion [31]. One study indicated that if 0.2% collagenase I was used for 10 min, the vascular matrix component could be obtained and if the 0.2% collagenase I was used for more than 30 min, the number of live adipocytes was reduced [39]. The addition of trypsin to collagenase I can accelerate the enzyme digestion. In future research, it is necessary to select the best type and concentration of enzyme to isolate stem cells quickly and efficiently.

The common Sc-ASCs are derived from the liquid fat of subcutaneous tissue, so the liquid-dispersed morphology is conducive to obtaining stem cells; while IPFP-ASCs are derived from the solid fat in IPFP, so the solid fat must undergo physical shearing and chemical digestion into liquid fat, which may affect the time to obtain stem cells and the quantity and proliferation capability of stem cells. Recent studies have shown that human second passage IPFP-ASC into the third passage IPFP-ASC requires approximately 48–60 h [26, 36, 38]. The total number of cells has a certain effect on cell proliferation capability, which may be related to intercellular communication and microenvironment [40, 41]. We should pay attention to these factors in order to

| Sources       | Culture efficiency                                           | Surface markers                                                                 | References |
|---------------|-------------------------------------------------------------|---------------------------------------------------------------------------------|------------|
| Marrow        | Strong differentiation potential and low culture efficiency in BM-MSCs | CD13+, CD29+, CD44+, CD49a+, F1, CD51+, CD73+, CD90+, CD105+, CD106+, CD166+, STRO-1+ | [19]       |
| IPFP          | Higher culture efficiency in IPFP-ASCs                      | CD13+, CD29+, CD44+, CD90+, CD105+, CD34+, CD56-, CD27-1+, STRO-1-            | [20, 21]  |
| Synovium      | Stronger chondrogenic differentiation in SF-MSCs than in IPFP-ASCs | CD44+, CD90+, CD105+, CD147+, CD34-, CD45-, CD117-, CD31-                    | [22, 23]  |
| Subcutaneous fat | Stronger differentiation potential in Sc-ASCs than in BM-MSCs | CD29+, CD44+, CD90+, CD13+, CD105+, CD34-, CD45-, CD31-, CD133-               | [24, 25]  |

IPFP-ASCs: infrapatellar fat pad adipose-derived stem cells; MSCs: mesenchymal stem cells; BM-MSCs: bone marrow mesenchymal stem cells; IPFP: infrapatellar fat pad; Sc-ASCs: subcutaneous adipose-derived stem cells.
obtain more stem cells with strong proliferation capacity. Francis et al. [39] found some optimized isolation methods such as frequent stirring, increasing collagenase, and using cell-specific coating flasks, which could obtain MSCs within 85 min and greatly shorten the time to obtain MSCs as compared with the previous 24–48 h. This makes it possible for time to use IPFP-ASCs in tissue transplantation of surgical emergencies. However, real application of IPFP-ASCs in acute trauma and transplantation surgery still requires a large number of clinical studies.

The culture conditions of IPFP-MSCs are similar to those of ordinary MSCs and commonly include 37°C, 5% CO₂, and saturated humidity. After primary culture, trypsin digestion is used for serial subcultivation.

4.2. Identification of IPFP-ASCs. There are many methods for the identification of stem cells. At present, the common identification methods include histology, immunohistochemical staining, qPCR, biochemical analysis, and image and mechanical detection, among which, the most commonly used method is immunohistochemical staining.

In 2006, the International Society for Cellular Therapy (ISCT) gave the definition of multipotent stromal cells and the bases to distinguish the multipotential stromal cells from hematopoietic stem cells as follows: (1) cell adhesion growth in vitro; (2) positive expression of CD44, CD73, CD90, and CD105 (positive detection rate of flow cytometry > 95%) and negative expression of CD11b, CD14, CD19, CD34, CD45, CD79a, and HLA-DR (the positive detection rate of flow cytometry < 2%); and (3) having the capabilities to differentiate into osteoblasts, adipocytes, and cartilage cells in vitro in specific culture conditions. IPFP-ASCs are not good for staining using low-affinity nerve growth factor receptors or STRO-1 [42]. In addition, IPFP-ASCs have higher expression levels of CD34, CD45, and CD166 than BM-MSCs, which suggests that IPFP-ASCs are different from BM-MSCs, but both still have similar surface markers such as CD73, CD90, and CD105 [26]. In the posttenth passage IPFP-ASC surface, there is the expression of CD13, CD44, CD90, and CD105 and occasionally the expression of 3G5, but no expression of LNGFR, STRO-1, CD34, and CD56 [28]. In the third to fifth passage IPFP-ASCs, the expression of CD13, CD45, and CD43 is negative and the expression of CD29, CD44, and CD90 is positive [43]. A systematic study on IPFP-ASCs shows that the surface antigens of IPFP-ASCs are CD9+, CD10+, CD13+, CD29+, CD44+, CD49e+, CD59+, CD105+, CD106+, and CD166+ [21]. So far, no specific markers have been found during IPFP-ASC culture, which may be related to the coexistence of multiple differentiated directional cells, so it is necessary to screen the unique target cells [26].

4.3. Differentiation Potential of IPFP-ASCs. MSC directional differentiation has always been a hot topic. The studies on inducing IPFP-ASC differentiation are mainly about chondrogenic differentiation and secondly about osteogenic differentiation and adipogenic differentiation. Certainly, there are a few studies on MSC differentiation to other directions. This article gives the introduction one by one as follows.

4.3.1. Chondrogenic Differentiation. At present, there are three main methods to induce chondrogenic differentiation including (1) regulation of physical factors for culture medium, (2) utilization of paracrine and intercellular interaction by coculture with other cells, and (3) differentiation-related gene transfection. However, it has been unclear which factor has stronger effect on differentiation and what interactions are present among the three factors. These issues remain to be further investigated.

Adjusting the inorganic culture environment by changes of biophysical factors may obtain different culture efficacies. Hydrostatic pressure plays an important role in IPFP-ASC chondrogenic differentiation [34]. Intermittent hydrostatic pressure may have a stronger effect on the chondrogenic differentiation of cartilage progenitor cells than on the chondrogenic differentiation of IPFP-ASCs [44]. Hypoxia (5%) is conducive to IPFP-ASC chondrogenic differentiation but can decrease IPFP-ASC osteogenic differentiation in mice [45]. Hyaluronic acid is an important extracellular matrix for chondrogenesis. The culture medium containing 25% hyaluronic acid is very conducive to IPFP-ASC chondrogenic differentiation, but culture medium containing 25% to 75% hyaluronic acid has no effect on the proliferation capability of IPFP-ASCs [5]. The cartilage similar to the structure and function of natural cartilage can be obtained by controlling the oxygen concentration of hydrogel and the surrounding environment [46]. The chondrocyte-laden hydrogels supported by a superficial layer of stem cells allow MSCs to have stronger chondrogenic differentiation potential, suggesting that the orderly environment is more conducive to MSC differentiation [38]. The recent studies on chondrogenic differentiation of MSCs and IPFP-ASCs are shown in Table 2.

Because IPFP is near the synovium and cartilage, IPFP-ASCs in IPFP may be induced to differentiate into chondrocytes by the growth factor secreted by its surrounding cells [21]. An in vivo 3D culture of IPFP-ASCs indicates that the cartilage matrix scaffold treated by TGF-β3 and the gelatum treated by TGF-β1 promote IPFP-ASC chondrogenic differentiation [57, 58]. The coculture of IPFP-ASCs with articular cartilage cells and hyaluronic acid can promote IPFP-ASC chondrogenic differentiation and prevent the occurrence of hypertrophic articular cartilage [48]. Above studies suggest that there are close communications between cells and the surrounding environment.

In addition, there are studies on IPFP-ASC differentiation at gene level. Bravo et al. [32] have found that during IPFP-ASC chondrogenic differentiation, the expressions of PTFR and MMP13 are similar between the patients with knee osteoarthritis and the individuals with healthy knees, but the expressions of OPG, FGF2, TGF, and MMP3 are significantly lower in the patients with knee osteoarthritis than in the individuals with healthy knees.

4.3.2. Osteogenic Differentiation. Osteogenic differentiation is also an important research direction of IPFP-ASCs. Compared with chondrogenic differentiation, the studies about osteogenic differentiation mainly focus on gene regulation and external scaffold construction, but there are also a few studies about cytokines. Osteogenic differentiation potential
| Year | Species | Cells | Factors | Outcome | Reference |
|------|---------|-------|---------|---------|-----------|
| 2019 | Sheep   | IPFP-ASCs | Nanofiber polycaprolactone | Promoting chondrogenic differentiation | [47] |
| 2018 | Human   | BM-MSCs | Microfluidic model technology | Inducing chondrogenic differentiation | [12] |
| 2018 | Human   | IPFP-ASCs | Gelatin scaffolds with aligned holes or random holes | Better chondrogenic differentiation in the gelatin scaffolds with aligned holes than in the gelatin scaffolds with random holes | [11] |
| 2018 | Human   | IPFP-ASCs | Coculture with platelet-rich plasma | Failing to promote chondrogenic differentiation | [48] |
| 2018 | Human   | ASCs from Lonza (Basel, Switzerland) | Second passage ASCs treated using endothelin-1 | Unfavourable for chondrogenic differentiation | [49] |
| 2018, 2012 | Human | IPFP-ASCs | Coculture with articular chondrocytes in hypoxia (5%) | Promoting chondrogenic differentiation | [50, 51] |
| 2017 | Human   | IPFP-ASCs | Coculture with hyaluronic acid nanoparticles | Promoting chondrogenic differentiation and preventing articular cartilage thickening and inflammation | [52] |
| 2017 | Human   | IPFP-ASCs | Culture with different material scaffolds in hypoxia (5%) | Hypoxia enhances cell viability and the expression of chondrogenic markers, and cellular response is superior with polycaprolactone than with hyaluronic acid | [53] |
| 2017 | Human   | IPFP-ASCs | Indirect coculture with osteoarthritis-derived articular chondrocytes | Promoting chondritic phenotypic recovery and IPFP-ASC chondrogenic differentiation in osteoarthritis | [54] |
| 2017 | Human   | IPFP-ASCs | Culture of ascorbic acid-treated IPFP-ASCs | The hardness of matrix is unchanged, but the chondrogenic differentiation potential is enhanced | [55] |
| 2017 | Human   | IPFP-ASCs and Sc-ASCs | The culture medium containing TGF-β family-related growth factors | Promoting chondrogenic differentiation | [36] |
| 2017 | Human   | IPFP-ASCs | Knocking out RHEB | Decreasing chondrogenic and osteogenic differentiation | [56] |
| 2016 | Human   | IPFP-ASCs | Porous cartilage extracellular matrix stent containing TGF-β3 | Continuously promoting chondrogenic differentiation | [57] |
| 2017 | Human   | IPFP-ASCs | Injectable hydrogel containing TGF-β1 and H2O2 | H2O2 allows the hydrogels to create a high-pressure environment which combined with TGF-β1 continuously promotes chondrogenic differentiation | [58] |
| 2016 | Pig     | IPFP-ASCs | Poly(ε-caprolactone) membrane | Inducing stem cells to form cartilage matrix, which enhances chondrogenic differentiation | [59] |
| 2016 | Sheep   | IPFP-ASCs | Culture of IPFP-ASCs under low-intensity pulsed ultrasound | Increased expression of cartilage gene | [60] |
| 2016 | Human   | IPFP-ASCs | Coculture with rat chondrocytes and acellular dermal matrix | Promoting cartilage formation and infiltration | [61] |
| 2016 | Human   | IPFP-ASCs | Coculture with osteoarthritis-derived articular chondrocytes | Failing to promote chondrogenic differentiation | [62] |
| 2015 | Pig     | IPFP-ASCs | Culture of IPFP-ASCs under dynamic pressure | Dynamic pressure slightly promotes chondrogenic differentiation and is conducive to structural stability | [63] |
| 2015 | Human   | IPFP-ASCs | Implantation of CD44 and IPFP-ASCs into TGF-β3 eluting ECM-derived stents | Producing more sulfated glycosaminoglycan and type II collagen, which promotes chondrogenic differentiation | [64] |
| 2011 | Bear    | Sc-ASCs | Pellet culture | Promoting chondrogenic differentiation | [65] |
| 2011 | Cattle  | IPFP-ASCs | The 3rd to 12th passage IPFP-ASCs | Unfavourable for chondrogenic differentiation | [7] |
| 2009 | Human   | BM-MSCs | Culture of BM-MSCs with dexamethasone | Promoting chondrogenic differentiation by enhancing expression of cartilage extracellular matrix genes | [66] |
| 2003 | Human   | IPFP-ASCs | Embedded with fibrin glue followed by culture in cartilage medium | Occurrence of chondrogenic differentiation after 6-week culture | [1] |

ASCs: adipose-derived stem cells; MSCs: mesenchymal stem cells; IPFP-ASCs: infrapatellar fat pad adipose-derived stem cells; BM-MSCs: bone marrow mesenchymal stem cells; Sc-ASCs: subcutaneous adipose-derived stem cells; RHEB: ras homolog enriched in brain; TGF-β3: transforming growth factor-β3; ECM: extracellular matrix.
is stronger in the IPFP-ASCs from obese mice than in the IPFP-ASCs from emaciated mice [67]. Osteogenic capability of IPFP-ASCs is not significantly different from BM-MSCs [3] and SF-MSCs [4]. IPFP-ASCs only produce bone precursor protein when induced by the culture medium containing vitamin C and inorganic phosphorus, but bone formation protein-2 (BMP-2) can induce IPFP-ASC osteogenic differentiation [1]. After coculture of fetal cartilage with IPFP-ASCs on polycaprolactone scaffold, the expressions of type II collagen and polyproteoglycan significantly decrease, but

| Year | Species | Cells | Factors | Outcome | Reference |
|------|---------|-------|---------|---------|-----------|
| 2018 | Human   | Sc-ASCs (epididymal fat pads) | Knocking out FAK gene | Promoting osteogenic differentiation | [69] |
| 2018 | Human   | Sc-ASCs | AtECM | Reducing the activity in early osteogenesis | [70] |
| 2017 | Human   | IPFP-ASCs | Coculture with fetal cartilage on polycaprolactone scaffold | Reduced type II collagen and polyproteoglycan and increased Indian hedgehog factor | [68] |
| 2017 | Human   | IPFP-ASCs | RHEB overexpression in IPFP-ASCs | Promoting osteogenic differentiation | [56] |
| 2016 | Human   | ASCs from Life Technology (USA) | MSCs cultured in 20%, 40%, and 60% FB scaffolds | Promoting osteogenic differentiation, and osteogenic differentiation is more obvious in 40% and 60% FB scaffolds | [71] |
| 2016 | Human   | ASCs from Life Technology (USA) | Scaffolds with large stiffness and small aperture | Osteogenesis is preferential | [71] |
| 2016 | Mice    | Sc-ASCs (inguinal fat pads) | The 3rd to 12th passage Sc-ASCs | Increased osteogenic differentiation | [6] |
| 2016 | Mice    | Sc-ASCs (inguinal fat pads) | Low-density sowing | Toward osteogenic differentiation | [6] |
| 2015 | Human   | Sc-ASCs | Osteogenic induction medium containing GLP-1 | Promoting osteogenic differentiation | [72] |
| 2014 | Rat     | Sc-ASCs (inguinal fat pad) | Medium containing rhPDGF-BB | Promoting osteogenic differentiation | [73] |
| 2014 | Human   | Sc-ASCs | Amplification on BM-ECM | Producing more osteoblasts | [74] |
| 2014 | Human   | Sc-ASCs | Subcutaneous implantation of MSCs induced by BM-ECM in nude mice | Producing more bone tissue | [74] |
| 2014 | Human   | ASCs from Lonza (Basel, Switzerland) | Addition of fullerol | Improving osteogenic potential | [75] |
| 2013 | Mice    | IPFP-ASCs | Obesity | Promoting osteogenesis | [67] |
| 2012 | Mice    | Sc-ASCs | Inhibiting zfp467 gene | Stimulating osteoblast development | [76] |
| 2012 | Rat     | Sc-ASCs (inguinal fat pads) | Mechanical load or maintaining static stretching | Promoting osteogenesis | [77] |
| 2011 | Human   | Sc-ASCs | Noggin gene knockout | Enhancing osteogenic differentiation | [78] |
| 2011 | Human   | Sc-ASCs | BMP-2 | Enhancing osteogenic potential | [78] |
| 2011 | Bear    | Sc-ASCs | Bone growth factor | Promoting osteogenesis | [65] |
| 2011 | Cattle  | IPFP-ASCs | Multiple passages | Toward osteogenic differentiation | [7] |
| 2010 | Mice    | Sc-ASCs (inguinal fat pads) | shh-N overexpression in ASCs | Promoting osteogenic differentiation | [79] |
| 2009 | Mice    | Sc-ASCs (inguinal fat pads) | Inhibition of histone deacetylase activity in reduced oxygen environment | Promoting osteogenic differentiation | [80] |
| 2008 | Pig     | Sc-ASCs | rhBMP-6 overexpression in Sc-ASCs | Inducing bone formation and obtaining spinal fusion | [81] |
| 2006 | Rat     | Sc-ASCs (inguinal fat pads) | Runx-2 overexpression in Sc-ASCs | Enhancing osteoblastic differentiation | [82] |
| 2003 | Human   | IPFP-ASCs | BMP-2 cDNA overexpression in IPFP-ASCs | Promoting osteogenesis | [1] |
| 2002 | Rat     | BM-MSCs | Fluid flow | Increasing mineralized matrix deposition in a dose-dependent manner | [83] |

ASCs: adipose-derived stem cells; IPFP-ASCs: infrapatellar fat pad adipose-derived stem cells; Sc-ASCs: subcutaneous adipose-derived stem cells; AtECM: adipose tissue extracellular matrix; RHEB: ras homolog enriched in brain; FB: firming buffer; GLP-1: glucagon-like peptide-1; rhPDGF-BB: recombinant human platelet-derived growth factor; BM-ECM: bone marrow-extracellular matrix; BMP-2: bone morphogenetic protein-2; shh-N: N-terminal Sonic Hedgehog; rhBMP-6: recombinant human bone morphogenetic protein-6.
the expression of Indian hedgehog factor significantly increases, suggesting that children cartilage and polycaprolactone have strong osteogenic effect and weak chondrogenic effect on IPFP-ASCs [68]. The recent studies on osteogenic differentiation of ASCs and IPFP-ASCs are shown in Table 3.

4.3.3. Adipogenic Differentiation. Due to limited utilization of differentiated adipocytes, adipogenic differentiation is not the main research direction of IPFP-ASCs, but it is still an important part of MSCs. Adipogenic differentiation potential is stronger in IPFP-ASCs than in BM-MSCs [3] and SF-MSCs [4]. Obese mice have stronger IPFP-ASC adipogenic differentiation potential than thin mice [67]. Hyaluronic acid also can enhance adipogenic differentiation [52]. Lopa et al. [84] have reported that IPFP-ASC adipogenic differentiation potential is similar between young people and old people. This is different from that IPFP-ASC chondrogenic differentiation potential is stronger in young people than in old people, which remains to be further explored. Table 4 shows the articles on the adipogenic differentiation-related factors.

| Year | Species | Cells | Factors | Outcome | Reference |
|------|---------|-------|---------|---------|-----------|
| 2018 | Human   | ASCs from Lonza (Basel, Switzerland) | Treated with ET-1 | Promoting adipogenic differentiation | [50] |
| 2018 | Human   | ASCs from Lonza (Basel, Switzerland) | Inducing ASCs after inhibiting ET receptor | Promoting adipogenic differentiation | [50] |
| 2017 | Human   | IPFP-ASCs | Hyaluronic acid | Promoting adipogenic differentiation | [52] |
| 2017 | Human   | IPFP-ASCs | RHEB overexpression in IPFP-ASCs | Promoting adipogenic differentiation | [56] |
| 2017 | Human   | Sc-ASCs | Addition of 2, 5, and 10 μm of pyrrentin | Lipid accumulation is the most marked in 2 μm of pyrrentin | [85] |
| 2016 | Human   | Sc-ASCs | miRNA-29b overexpression in Sc-ASCs | Promoting adipogenic differentiation | [86] |
| 2016 | Human   | ASCs from Life Technology (USA) | ASCs cultured in 20%, 40%, and 60% FB scaffolds | Promoting adipogenic differentiation | [71] |
| 2016 | Human   | ASCs from Life Technology (USA) | Scaffolds with low stiffness and large aperture | Promoting adipogenic differentiation | [71] |
| 2016 | Mice    | Sc-ASCs (inguinal fat pads) | The 3rd to 12th passage Sc-ASCs | Inhibiting adipogenic differentiation | [6] |
| 2015 | Human   | Sc-ASCs | Adipogenic induction medium containing GLP-1 | Inhibiting adipogenic differentiation | [72] |
| 2014 | Rat     | Sc-ASCs (inguinal fat pads) | ERK inhibitor (PD98059) | Promoting adipogenic differentiation | [73] |
| 2014 | Mice    | Sc-ASCs (inguinal fat pads) | Removing ovaries | Promoting adipogenic differentiation | [87] |
| 2013 | Mice    | IPFP-ASCs | Obesity | Promoting adipogenic differentiation | [67] |
| 2013 | Rat     | Sc-ASCs (inguinal fat pads) | Secretory factors from rat adipose tissue explants | Promoting adipogenic differentiation | [88] |
| 2012 | Pig     | Sc-ASCs | A differentiation inducer which consisted by dexamethasone, insulin, and methylxanthine and combined with myostatin | Inhibiting adipogenic differentiation | [89] |
| 2012 | Rat     | Sc-ASCs (inguinal fat pads) | Mechanical cyclic loading on Sc-ASCs | Inhibiting adipogenic differentiation | [77] |
| 2011 | Bear    | Sc-ASCs | Adipogenic induction medium | Lipid droplet accumulation | [65] |
| 2011 | Cattle  | IPFP-ASCs | The fifth passage | Inhibiting adipogenic differentiation | [7] |
| 2010 | Mice    | Sc-ASCs (inguinal fat pads) | Blocking endogenous hedgehog signaling pathway and adding hedgehog antagonists | Promoting adipogenic differentiation | [79] |
| 2009 | Mice    | ASCs (inguinal fat pads) | Transient exposure to histone deacetylase inhibitor under hypoxia | Inhibiting adipogenic differentiation | [80] |
| 2006 | Rat     | Sc-ASCs (inguinal fat pads) | Runx-2 overexpression in Sc-ASCs | Inhibiting adipogenic differentiation | [82] |

ASCs: adipose-derived stem cells; IPFP-ASCs: infrapatellar fat pad adipose-derived stem cells; ET-1: endothelin-1; ATECM: adipose tissue extracellular matrix; RHEB: ras homolog enriched in brain; FB: firming buffer; GLP-1: glucagon-like peptide-1; ERK: extracellular signal-related kinase.
ASCs show marked therapeutic effects. ASCs have good effects on the patients with advanced OA is decreased [102]. IPFP-chondrogenic differentiation [9].

4.3.4. Inducing Differentiation toward Other Sorts of Body Cells. At present, there are no reports on IPFP-ASC differentiation into other sorts of body cells besides chondrogenic, osteogenic, or adipogenic differentiation. However, MSCs may be differentiated into multilineage cells. MSCs have the potential to differentiate into osteoclasts [90]. MSCs also show cardiomyocyte-like, skeletal muscle cell-like, tendon-like, and epithelial cell-like differentiation [91, 92]. Canine MSCs can be immortalized with SV40 gene, and then the immortalized MSCs are transplanted into busulfan-induced seminiferous tubules of infertile mice and show germ cell differentiation potential [93]. The studies on differentiation toward other histiocytes are shown in Table 5.

5. Applications of IPFP-ASCs and MSCs

IPFP-ASCs are generally considered to be more promising stem cells because IPFP as an inflamed tissue must be resected to relieve pain in knee arthroplasty, so obtaining IPFP-ASCs avoids the damage to patients as compared with obtaining bone marrow-derived MSCs, and IPFP-ASC isolation procedure is easy to operate. The injection of IPFP-ASCs can effectively relieve pain and improve knee joint function in osteoarthritis [100, 101]. Koh et al. [100, 101] reported that after injection of platelet-rich plasma containing a mean of 1.89 x 10^6 IPFP-ASCs into arthritic knees, the mean Lysholm, Tegner activity scale, and VAS scores improved significantly and no major adverse events related to the injections were observed; the therapeutic effects were positively associated with the number of IPFP-ASCs but negatively associated with disease duration and patient’s age. IPFP-ASCs show marked therapeutic effects in young patients and patients with early cartilage deformation [98, 99]. The chondrogenic differentiation potential of IPFP-ASCs from the patients with advanced OA is decreased [102]. IPFP-ASCs have good effects on osteoarthritis in stages I and II [103]. IPFP-ASCs may be induced to produce muscle-specific cytoskeleton proteins which are conducive to muscle regeneration [9].

Besides subpatellar fat pad, MSCs are also obtained from subgluteal fat pad, abdominal liposuction, and inguinal fat pads. MSCs from these different sources all show good functional characteristics. The postoperative evaluation is better in BM-MSC transplantation combined with microfracture than in microfracture alone [104]. The outcomes of subgluteal fat pad-derived MSC implantation for cartilage repair of osteoarthritic knees seem encouraging [105]. The graft survival and the volumes of fat and newly generated connective tissue all are significantly higher in abdominal liposuction-derived MSC-enriched fat grafts than in fat grafts alone, suggesting that MSC-enriched graft could render lipofilling a reliable alternative to major tissue augmentation, such as breast surgery or major flap surgery [106]. A combination of percutaneously injected autologous adipose tissue-derived stem cells, hyaluronic acid, platelet-rich plasma, and calcium chloride may regenerate bone and cartilage in the patients with hip osteonecrosis or knee osteoarthritis [107]. The applications of IPFP-ASCs and MSCs are shown in Table 6.

At present, most studies on IPFP-ASC are about in vitro IPFP-ASC culture and IPFP-ASC animal experiment. In recent years, 3D printing technology has solved the nonmolding problem of stem cell differentiation and can construct complex human structure and improve cell differentiation efficiency and/or posttransplantation survival ability. Stem cells may be differentiated into cartilage by microfluidics without the requirement of growth factors [12]. With the development of stem cell technology and biomaterial science, IPFP-ASCs will be more and more widely used.

6. Summary and Outlook

Compared with other MSCs, IPFP-ASCs have the following characteristics: (1) IPFP-ASC isolation is relatively easy, and more stem cells may be obtained from the IPFP. (2) IPFP-ASCs have strong proliferation capability and differentiation potential, and IPFP-ASCs are more superior in chondrogenic differentiation and osteogenic differentiation than BM-MSCs and Sc-ASCs. (3) IPFP-ASCs can secrete a variety...
of cytokines. The injection of IPFP-ASC culture supernatant fluid into the knee joint can relieve inflammatory pain and restore partial joint function, which is related to miR-100-5p-abundant exosomes produced by IPFP-ASCs in the supernatant fluid [115]. This demonstrates that IPFP-ASCs have broad prospects in the treatment of knee osteoarthritis. (4) IPFP-ASCs may be used in treatment of osteoarthritis along with other methods. Due to IPFP anatomical position, the surface markers of IPFP-ASCs are similar to those of other cells around the knee joint, so IPFP-ASCs can be implanted in the knee joint with other synthetic grafts to reduce immunologic rejection. (5) IPFP-ASCs are more suitable to molding culture. (6) Other aspects include the following. IPFP-ASCs have immunomodulatory effect. IPFP-ASCs as adult stem cells also are used in the reconstruction of various tissues.

In summary, many problems on IPFP-ASCs remain to be solved, but more and more attention has been paid to it because IPFP collection is easy, IPFP contains a large number of stem cells, IPFP-ASC isolation is simple, and IPFP-ASCs have multidirectional differentiation potential. IPFP-ASCs will be a promising stem cell source in regenerative medicine.

Table 6: Applications of IPFP-ASCs and MSCs.

| Year  | Species            | Diseases                        | Cells            | Methods                                                                 | Outcome                                                                 | Reference |
|-------|--------------------|---------------------------------|------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------|
| 2018  | Human              | Osteoarthritis                  | Ha-MSCs          | Injection of Ha-MSCs into knee joint cavity                             | No severe side effects, relieving pain, restoring function, increasing cartilage mass | [108]     |
| 2018  | Human              | Osteoarthritis                  | Sc-ASCs          | Injection of Sc-ASCs into knee joint cavity                             | Reducing cartilage defects by regeneration of hyaline-like articular cartilage | [109]     |
| 2018  | Human              | Osteoarthritis                  | In vitro model of meniscal tear | Injection of PRG into knee joint cavity Coculture medium of Sc-MSCs and TGF-β was added into bovine meniscus tear in vitro model | Relieving pain Showing strong matrix-sulfated proteoglycan deposition and promoting healing | [11]      |
| 2016  | Human              | Osteoarthritis                  | Sc-ASCs          | Injection of Sc-ASCs (2 × 10^6, 10 × 10^6, and 50 × 10^6, respectively) into knee joint cavity | Relieving pain and restoring function, especially in 2 × 10^6 Sc-ASCs | [111]     |
| 2015  | Human              | Bone destruction of long bone   | Sc-ASCs          | Transplantation of three-dimensional graft from autologous Sc-ASCs and decalcified bone matrix into knee joint | Promoting osteogenesis in bone nonunions and restoring anatomic structure without oncological side effects | [112]     |
| 2014  | Rabbit             | Osteoporosis                    | Sc-ASCs          | Injection of Sc-ASCs into knee joint cavity                             | Promoting bone regeneration in vivo and relieving osteoporosis | [113]     |
| 2014  | Rat                | Abdominal aortic aneurysm       | Sc-ASCs          | Injection of Sc-ASCs into abdominal aortic aneurysm                     | Promoting the expression of elastin in smooth muscle and facilitating the reconstruction of elastic membrane | [114]     |
| 2012  | Human              | Osteoarthritis                  | IPFP-ASCs        | Injection of IPFP-ASCs into knee joint cavity                         | Effectively relieve pain and improve the function of knee joint | [99]      |
| 2011  | Human              | Calvarial defects               | Sc-ASCs          | Transplantation of Sc-ASCs with Noggin knockout into the destroyed skull in mice | Rapidly repairing mouse calvarial defects | [78]      |
| 2010  | Mice               | Tibia destruction               | Sc-ASCs          | Transplantation of ASCs stimulated by N-terminal sonic hedgehog into tibial defect | Enhancing osteogenesis | [79]      |
| 2008  | Pig                | Lumbar disc degeneration        | IPFP-ASCs        | Injection of IPFP-ASCs with rhBMP-6 overexpression into lumbar paravertebral muscle IPFP-ASCs were embedded into fibrin glue nodules, for inducing chondrogenic cells, and were placed in osteogenic media containing BMP-2 for inducing osteogenic cells, respectively. And then these cells were transplanted into the hind legs of nude mice | Spinal fusion and new bone formation | [81]      |
| 2003  | Human              | Osteoarthritis                  | IPFP-ASCs        | Injection of IPFP-ASCs with rhBMP-6 overexpression into lumbar paravertebral muscle IPFP-ASCs were embedded into fibrin glue nodules, for inducing chondrogenic cells, and were placed in osteogenic media containing BMP-2 for inducing osteogenic cells, respectively. And then these cells were transplanted into the hind legs of nude mice | Cartilage formation induced by fibrin glue nodules, bone formation induced by BMP-2, and bone marrow cavity formation in the hind legs of the osteogenic culture group | [1]       |

IPFP-ASCs: infrapatellar fat pad derived stem cells; MSCs: mesenchymal stem cells; Ha-MSCs: human amniotic mesenchymal stromal cells; Progenza (PRG): comprises in vitro expanded mesenchymal stem cells derived from human donor adipose tissue combined with cell culture supernatant; TGF-β: transforming growth factor-β; rhBMP-6: recombinant human bone morphogenetic protein-6; BMP-2: bone morphogenetic protein-2.
and increasing posttransplantation regeneration rate. We believe that the key problem resolved in the future is that the methods for IPFP-ASC directional differentiation will be safe, controllable, and manipulable.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yu-chen Zhong and Shi-chun Wang equally contributed to this work.

Acknowledgments

This study was supported by the Key Projects of Natural Science Foundation of Liaoning Province (No. 20170540998).

References

[1] J. L. Dragoo, B. Samimi, M. Zhu et al., “Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads,” Journal of Bone and Joint Surgery British Volume, vol. 85-B, no. 5, pp. 740–747, 2003.

[2] S. Neri, S. Guidotti, N. L. Lilli, L. Cattini, and E. Mariani, “Infrapatellar fat pad-derived mesenchymal stromal cells from osteoarthritis patients: in vitro genetic stability and replicative senescence,” Journal of Orthopaedic Research, vol. 35, no. 5, pp. 1029–1037, 2017.

[3] A. English, E. A. Jones, D. Corscadden et al., “A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis,” Rheumatology, vol. 46, no. 11, pp. 1676–1683, 2007.

[4] J. García, K. Wright, S. Roberts et al., “Characterisation of synovial fluid and infrapatellar fat pad derived mesenchymal stromal cells: the influence of tissue source and inflammatory stimulus,” Scientific Reports, vol. 6, no. 1, 2016.

[5] D. C. Ding, K. C. Wu, H. L. Chou, W. T. Hung, H. W. Liu, and T. Y. Chu, “Human infrapatellar fat pad-derived stromal cells have more potent differentiation capacity than other mesenchymal cells and can be enhanced by hyaluronic,” Cell Transplantation, vol. 24, no. 7, pp. 1221–1232, 2015.

[6] Y. Liu, Z. Zhang, C. Zhang et al., “Adipose-derived stem cells undergo spontaneous osteogenic differentiation in vitro when passaged serially or seeded at low density,” Biotechnic & Histochemistry, vol. 91, no. 5, pp. 369–376, 2016.

[7] Y. Zhao, S. D. Waldman, and L. E. Flynn, “The effect of serial passaging on the proliferation and differentiation of bovine adipose-derived stem cells,” Cells, Tissues, Organs, vol. 195, no. 5, pp. 414–427, 2012.

[8] I. R. Klein-Wieringa, M. Kloppeenburg, Y. M. Bastiaansen-Jenniskens et al., “The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype,” Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 851–857, 2011.

[9] D. Huri, S. Hamsici, E. Ergene, G. Huri, and M. N. Doral, “Infrapatellar fat pad-derived stem cell-based regenerative strategies in orthopedic surgery,” Knee Surgery & Related Research, vol. 30, no. 3, pp. 179–186, 2018.

[10] D. Knus, S. Sivell, T. Longworth et al., “Safety, tolerability and efficacy of intra-articular progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study,” Journal of Translational Medicine, vol. 16, no. 1, p. 49, 2018.

[11] A. Bhattacharjee and D. S. Katti, “Pore alignment in gelatin scaffolds enhances chondrogenic differentiation of infrapatellar fat pad derived mesenchymal stromal cells,” ACS Biomaterials Science & Engineering, vol. 5, no. 1, pp. 114–125, 2019.

[12] S. Lopa, C. Mondadori, V. L. Mainardi et al., “Translational application of microfluidics and bioprinting for stem cell-based cartilage repair,” Stem Cells International, vol. 2018, Article ID 6594841, 14 pages, 2018.

[13] L. Yi-kai, S. Jin, and Z. Shi-zhen, “Anatomic measure of sub-patellar fat pad and its clinical significance,” The Journal of Cervicodynia And Lumbodynia, vol. 20, no. 3, pp. 181–182, 1999.

[14] N. Shabshin, M. E. Schweitzer, and W. B. Morrison, “Quadriceps fat pad edema: significance on magnetic resonance images of the knee,” Skeletal Radiology, vol. 35, no. 5, pp. 269–274, 2006.

[15] K. Takatoku, H. Sekiya, M. Hayashi, Y. Hoshino, and Y. Kariya, “Influence of fat pad removal on patellar tendon length during growth,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 13, no. 8, pp. 706–713, 2005.

[16] P. A. Zuk, M. Zhu, H. Muzzo et al., “Multilineage cells from human adipose tissue: implications for cell-based therapies,” Tissue Engineering, vol. 7, no. 2, pp. 211–228, 2001.

[17] M. Q. Wickham, G. R. Erickson, J. M. Gimble, T. P. Vail, and F. Guilak, “Multipotent stromal cells derived from the infrapatellar fat pad of the knee,” Clinical Orthopaedics and Related Research, vol. 412, pp. 196–212, 2003.

[18] R. Felimban, K. Ye, K. Traianedes et al., “Differentiation of stem cells from human infrapatellar fat pad: characterization of cells undergoing chondrogenesis,” Tissue Engineering Part A, vol. 20, no. 15–16, pp. 2213–2223, 2014.

[19] S. Halfon, N. Abramov, B. Grinblat, and I. Ginis, “Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging,” Stem Cells and Development, vol. 20, no. 1, pp. 53–66, 2011.

[20] W. S. Khan, A. B. Adesida, and T. E. Hardingham, “Hypoxic conditions increase hypoxia-inducible transcription factor 2α and enhance chondrogenesis in stem cells from the infrapatellar fat pad of osteoarthritis patients,” Arthritis Research & Therapy, vol. 9, no. 3, article R55, 2007.

[21] N. K. Dubey, V. K. Mishra, R. Dubey et al., “Combating osteoarthritis through stem cell therapies by rejuvenating cartilage: a review,” Stem Cells International, vol. 2018, Article ID 5421019, 13 pages, 2018.

[22] C. De Bari, F. Dell’Accio, and F. P. Luyten, “Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age,” Arthritis and Rheumatism, vol. 44, no. 1, pp. 85–95, 2001.

[23] Y. Sakaguchi, I. Sekiya, K. Yagishita, and T. Muneta, “Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source,” Arthritis and Rheumatism, vol. 52, no. 8, pp. 2521–2529, 2005.

[24] G. Zeng, K. Lai, J. Li et al., “A rapid and efficient method for primary culture of human adipose-derived stem cells,” Organogenesis, vol. 9, no. 4, pp. 287–295, 2014.

[25] F. J. Van Milligen, M. J. Oedayrajsingh Yarma, M. N. Helder et al., “Adipose tissue-derived stem cell yield and growth
characteristics are affected by the tissue harvesting procedure,” in 52nd Annual Meeting of the Orthopaedic Research Society, University Medical Center, Amsterdam, The Netherlands.

[26] R. J. F. C. do Amaral, H. V. Almeida, D. J. Kelly, F. J. O'T. Mesallati, C. T. Buckley, and D. J. Kelly, “Adipose-derived mesenchymal stem cells as a potential source for cell-based adipose tissue repair strategies,” Cell Proliferation, vol. 45, no. 2, pp. 111–120, 2012.

[27] I. Roato, D. Alotto, D. C. Belisario et al., “Adipose derived-mesenchymal stem cells viability and differentiating features for orthopaedic reparative applications: banking of adipose tissue,” Stem Cells International, vol. 2016, Article ID 4968724, 11 pages, 2016.

[28] W. Wei, E. Rudjito, N. Fahy et al., “The infrapatellar fat pad from diseased joints inhibits chondrogenesis of mesenchymal stem cells,” European Cells & Materials, vol. 30, pp. 303–314, 2015.

[29] U. Skalska, M. Prochorec-Sobieszek, and E. Kontny, “Osteoblastic potential of infrapatellar fat pad-derived mesenchymal stem cells from rheumatoid arthritis and osteoarthritis patients,” International Journal of Rheumatic Diseases, vol. 19, no. 6, pp. 577–585, 2016.

[30] B. Bravo, J. M. Argüello, A. R. Gortazar, F. Forriol, and J. Vaquero, “Modulation of gene expression in infrapatellar fat pad-derived mesenchymal stem cells in osteoarthritis,” Cartilage, vol. 9, no. 1, pp. 55–62, 2016.

[31] M. Ruiz, M. Maumus, G. Fonteneau et al., “TGFβ is involved in the chondrogenic differentiation of mesenchymal stem cells and is dysregulated in osteoarthritis,” Osteoarthritis and Cartilage, vol. 27, no. 3, pp. 493–503, 2019.

[32] C. T. Buckley, T. Vinardell, and D. J. Kelly, “Oxygen tension differentially regulates the functional properties of cartilaginous tissues engineered from infrapatellar fat pad derived MSCs and articular chondrocytes,” Osteoarthritis Cartilage, vol. 18, no. 10, pp. 1345–1354, 2010.

[33] I. Muñoz-Criado, J. Meseguer-Ripolles, M. Mellado-López et al., “Human suprapatellar fat pad-derived mesenchymal stem cells induce chondrogenesis and cartilage repair in a model of severe osteoarthritis,” Stem Cells International, vol. 2017, Article ID 4758930, 12 pages, 2017.

[34] E. López-Ruiz, G. Jiménez, W. Kwiatkowski et al., “Impact of TGF-β family-related growth factors on chondrogenic differentiation of adipose-derived stem cells isolated from lipoaspirates and infrapatellar fat pads of osteoarthritic patients,” European Cells & Materials, vol. 35, pp. 209–224, 2018.

[35] R. J. F. C. do Amaral, H. V. Almeida, D. J. Kelly, F. J. O’Brien, and C. J. Kearney, “Infrapatellar fat pad stem cells: from developmental biology to cell therapy,” Stem Cells International, vol. 2017, Article ID 6843727, 10 pages, 2017.

[36] T. Mesallati, C. T. Buckley, and D. J. Kelly, “Engineering cartilaginous grafts using chondrocyte-laden hydrogels supported by a superficial layer of stem cells,” Journal of Tissue Engineering and Regenerative Medicine, vol. 11, no. 5, pp. 1343–1353, 2017.

[37] L. Francis, S. Duchi, C. Onofrillo, C. di Bella, and P. F. M. Choong, “Adipose-derived mesenchymal stem cells in the use of cartilage tissue engineering: the need for a rapid isolation procedure,” Stem Cells International, vol. 2018, Article ID 8947548, 9 pages, 2018.

[38] B. Sridharan, S. M. Lin, A. T. Hwu, A. D. Lafkin, and M. S. Detamore, “Stem cells in aggregate form to enhance chondrogenesis in hydrogels,” PLoS One, vol. 10, no. 12, article e0141479, 2015.

[39] G. M. van Buul, E. Villafuertes, P. K. Bos et al., “Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture,” Osteoarthritis and Cartilage, vol. 20, no. 10, pp. 1186–1196, 2012.

[40] W. S. Khan, S. R. Tew, A. B. Adesa, and T. E. Hardingham, “Human infrapatellar fat pad-derived stem cells express the pericyte marker 3G5 and show enhanced chondrogenesis after expansion in fibroblast growth factor-2,” Arthritis Research & Therapy, vol. 10, no. 4, p. R74, 2008.

[41] M. H. Moon, S. Y. Kim, Y. J. Kim et al., “Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia,” Cellular Physiology and Biochemistry, vol. 17, no. 5-6, pp. 279–290, 2006.

[42] Y. Li, J. Zhou, X. Yang, Y. Jiang, and J. Gui, “Intermittent hydrostatic pressure maintains and enhances the chondrogenic differentiation of cartilage progenitor cells cultivated in alginate beads,” Development, Growth & Differentiation, vol. 58, no. 2, pp. 180–193, 2016.

[43] Y. Xu, P. Malladi, M. Chioi, E. Bekerman, A. J. Giaccia, and M. T. Longaker, “In vitro expansion of adipose-derived adult stromal cells in hypoxia enhances early chondrogenesis,” Tissue Engineering, vol. 13, no. 12, pp. 2981–2993, 2007.

[44] L. Luo, A. R. O’Reilly, S. D. Thorpe, C. T. Buckley, and D. J. Kelly, “Engineering zonal cartilaginous tissue by modulating oxygen levels and mechanical cues through the depth of infrapatellar fat pad stem cell laden hydrogels,” Journal of Tissue Engineering and Regenerative Medicine, vol. 11, no. 9, pp. 2613–2628, 2017.

[45] P. Vahedi, S. Jarolmasjed, H. Shafaei, L. Roshangar, J. Soleimani Rad, and E. Ahmadian, “In vivo articular cartilage regeneration through infrapatellar adipose tissue derived stem cell in nonfiber polycaprolactone scaffold,” Tissue & Cell, vol. 57, pp. 49–56, 2019.

[46] J. J. Liou, B. B. Rothrauff, P. G. Alexander, and R. S. Tuan, “Effect of platelet-rich plasma on chondrogenic differentiation of adipose- and bone marrow-derived mesenchymal stem cells,” Tissue Engineering Part A, vol. 24, no. 19-20, pp. 1432–1443, 2018.

[47] M. S. Lee, J. Wang, H. Yuan et al., “Endothelin-1 differentially directs lineage specification of adipose- and bone marrow-derived mesenchymal stem cells,” The FASEB Journal, vol. 33, no. 1, pp. 996–1007, 2018.

[48] A. B. Adesa, A. Mulet-Sierra, and N. M. Jomha, “Hypoxia mediated isolation and expansion enhances the chondrogenic capacity of bone marrow mesenchymal stromal cells,” Stem Cell Research & Therapy, vol. 3, no. 2, p. 9, 2012.

[49] S. E. Critchley, R. Eswarathooorthy, and D. J. Kelly, “Low-oxygen conditions promote sympathetic increases in chondrogenesis during co-culture of human osteoarthritic stem cells and
MSCs into adipocytes,

- Inhibition of histone deacetylase activity in reduced oxygen environment enhances the osteogenesis of mouse adipose-derived stromal cells,

- Nonvirally engineered porcine adipose tissue-derived stem cells: use in posterior spinal fusion,

- Runx 2 overexpression enhances osteoblastic differentiation and mineralization in adipose–derived stem cells in vitro and in vivo,

- Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner,

-進步和生理学的療法,”*European Cells & Materials*, vol. 27, pp. 298–311, 2014.

- Pyrintegrin induces soft tissue formation by transplanted or endogenous cells,”*Scientific Reports*, vol. 7, no. 1, article 36402, 2017.

- MicroRNA-29b promotes the adipogenic differentiation of human adipose tissue-derived stromal cells,”*Obesity*, vol. 24, no. 5, pp. 1097–1105, 2016.

- Adipogenic differentiation potential of adipose-derived mesenchymal stem cells from ovariec-tomized mice,”*Cell Proliferation*, vol. 47, no. 6, pp. 604–614, 2014.

- Secretory factors from rat adipose tissue explants promote adipogenesis and angiogenesis,”*Artificial Organs*, vol. 38, no. 2, pp. E33–E45, 2014.

- Different regulation role of myostatin in differentiating pig ADSCs and MSCs into adipocytes,”*Cell Biochemistry and Function*, vol. 30, no. 2, pp. 145–150, 2012.

- Epithelial differentiation of human adipose tissue-derived adult stem cells,”*Biochemical and Biophysical Research Communications*, vol. 330, no. 1, pp. 142–150, 2005.

- Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells,”*Circulation Research*, vol. 94, no. 2, pp. 223–229, 2004.

- Immortalization of canine adipose-derived mesenchymal stem cells and their seminiferous tubule transplantation,”*Journal of Cellular Biochemistry*, vol. 119, no. 4, pp. 3663–3670, 2018.

- Biophysical cues enhance myogenesis of human adipose derived stem/stromal cells,”*Biochemical and Biophysical Research Communications*, vol. 438, no. 1, pp. 180–185, 2013.

- Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives,”*Circulation*, vol. 109, no. 5, pp. 656–663, 2004.

- IFATS collection: adipose-derived stromal cells improve the foreign body response,”*Stem Cells*, vol. 26, no. 10, pp. 2691–2695, 2008.

- Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells,”*Biochemical and Biophysical Research Communications*, vol. 341, no. 4, pp. 1135–1140, 2006.

- Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo,”*Biochemical and Biophysical Research Communications*, vol. 328, no. 1, pp. 258–264, 2005.

- Neurogenic differentiation of murine and human adipose-derived stromal cells,”*Biochemical and Biophysical Research Communications*, vol. 294, no. 2, pp. 371–379, 2002.

- Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis,”*The Knee*, vol. 19, no. 6, pp. 902–907, 2012.

- Mesenchymal stem cell injections improve symptoms of knee osteoarthritis,”*Arthroscopy*, vol. 29, no. 4, pp. 748–755, 2013.

- Chondrogenesis of infrapatellar fat pad derived adipose stem cells in 3D printed chitosan scaffold,”*PLoS One*, vol. 9, no. 6, article e99410, 2014.

- Mesenchymal stem cells and their clinical applications in osteoarthritis,”*Cell Transplantation*, vol. 25, no. 5, pp. 937–950, 2016.

- Transplantation of autologous bone marrow-derived mesenchymal stem cells under arthroscopic surgery with microfracture versus microfracture alone for articular cartilage lesions in the knee: a multicenter prospective randomized control clinical trial,”*Regenerative Therapy*, vol. 11, pp. 106–113, 2019.

- Second-look arthroscopic evaluation of cartilage lesions after mesenchymal stem cell implantation in osteoarthritic knees,”*The American Journal of Sports Medicine*, vol. 42, no. 7, pp. 1628–1637, 2014.

- Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trial,”*The Lancet*, vol. 382, no. 9898, pp. 1113–1120, 2013.

- Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series,”*Journal of Medical Case Reports*, vol. 5, no. 1, 2011.

- Human adipose-derived mesenchymal stem cells for osteoarthritis: a pilot study with
long-term follow-up and repeated injections,” Regenerative Medicine, vol. 13, no. 3, pp. 295–307, 2018.

[109] C. H. Jo, Y. G. Lee, W. H. Shin et al., “Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial,” Stem Cells, vol. 32, no. 5, pp. 1254–1266, 2014.

[110] H. Sasaki, B. B. Rothrauff, P. G. Alexander et al., “In vitro repair of meniscal radial tear with hydrogels seeded with adipose stem cells and TGF-β3,” The American Journal of Sports Medicine, vol. 46, no. 10, pp. 2402–2413, 2018.

[111] Y.-M. Pers, L. Rackwitz, R. Ferreira et al., “Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase i dose-escalation trial,” Stem Cells Translational Medicine, vol. 5, no. 7, pp. 847–856, 2016.

[112] D. Dufrane, P. L. Docquier, C. Delloye, H. A. Poirel, W. André, and N. Aouassar, “Scaffold-free three-dimensional graft from autologous adipose-derived stem cells for large bone defect reconstruction: clinical proof of concept,” Medicine, vol. 94, no. 50, article e2220, 2015.

[113] X. Ye, P. Zhang, S. Xue, Y. Xu, J. Tan, and G. Liu, “Adipose-derived stem cells alleviate osteoporosis by enhancing osteogenesis and inhibiting adipogenesis in a rabbit model,” Cytotherapy, vol. 16, no. 12, pp. 1643–1655, 2014.

[114] X. Tian, J. Fan, M. Yu et al., “Adipose stem cells promote smooth muscle cells to secrete elastin in rat abdominal aortic aneurysm,” PLoS One, vol. 9, no. 9, article e108105, 2014.

[115] J. Wu, L. Kuang, C. Chen et al., “miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis,” Biomaterials, vol. 206, pp. 87–100, 2019.